Overview

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Exemestane